Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | HPGD | P15428 | 3/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.57 |
| ▸ | ESR1 | P03372 | 1/20 | 0.57 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.57 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.57 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.57 |
| ▸ | GGT1 | P19440 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL622344 | 0.81 | PTGS2 (0.43) | PTGS2HSD17B10KDM4ELMNACYP1A2 | |
| SCHEMBL2865396 | 0.80 | TSHR (0.43) | PTGS2HSD17B10KDM4ELMNAALDH1A1 | |
| SCHEMBL15889886 | 0.80 | PTGS2 (0.65) | PTGS2HSD17B10KDM4ELMNACYP1A2 | |
| SCHEMBL15889887 | 0.80 | PTGS2 (0.85) | PTGS2HSD17B10KDM4ELMNACYP1A2 | |
| SCHEMBL789771 | 0.79 | HSD17B10 (0.71) | PTGS2HSD17B10KDM4ELMNACYP1A2 | |
| SCHEMBL10705752 | 0.79 | HSD17B10 (0.71) | PTGS2HSD17B10KDM4ELMNACYP1A2 | |
| SCHEMBL5988737 | 0.79 | HSD17B10 (0.71) | PTGS2HSD17B10KDM4ELMNACYP1A2 | |
| SCHEMBL29669847 | 0.79 | HSD17B10 (0.71) | PTGS2HSD17B10KDM4ELMNACYP1A2 | |
| Aspirin SCHEMBL2782628 | 0.79 | KDM4E (0.80) | PTGS2HSD17B10KDM4ELMNACYP1A2 | |
| SCHEMBL4960087 | 0.79 | KDM4E (0.57) | PTGS2HSD17B10KDM4ELMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 609 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12480162-B2 | Detection of metastatic disease and related methods | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2025-11-25 | — | — | US | claimed |
| EP-3463434-B1 | IMMUNOTHERAPY FOR CANCER | EXCOSO A S (CZ) | 2024-12-25 | — | — | EP | claimed |
| US-20240122977-A1 | COMPOSITIONS AND METHODS FOR PARENTERAL ADMINISTRATION OF THERAPEUTIC AGENTS | EPICENTRX, INC. | 2024-04-18 | — | — | US | claimed |
| EP-3419676-B1 | ANTIMICROBIAL COMPOSITIONS AND USES THEREOF | UNIV TEXAS (US) | 2022-08-31 | — | — | EP | claimed |
| US-20220202838-A1 | COMBINATIONAL THERAPIES FOR TREATMENT OF CANCER COMPRISING A BACTERIOCHLOROPHYLL DERIVATIVE | MEMORIAL SLOAN-KETTERING CANCER CENTER | 2022-06-30 | — | — | US | claimed |
| US-20210379087-A1 | COMPOSITIONS FOR THE ELIMINATION OF SENESCENT CELLS | MEDIZINISCHE UNIVERSITÄT WIEN (AT) | 2021-12-09 | — | — | US | claimed |
| CN-113347969-A | Composition for eliminating senescent cells | 维也纳自然资源与生命科学大学 | 2021-09-03 | — | — | CN | claimed |
| US-20210252120-A1 | IMMUNOTHERAPY FOR CANCER | SOTIO a.s. (CZ) | 2021-08-19 | — | — | US | claimed |
| US-20210085736-A1 | IMMUNO-ONCOLYTIC MODIFIED VACCINIA TIAN TAN VIRUS AND METHODS OF TREATING CANCER | THE UNIVERSITY OF HONG KONG (HK) | 2021-03-25 | — | — | US | claimed |
| CN-112004545-A | Immuno-oncolytic modified vaccinia Tiantan virus and methods of treating cancer | 香港大学 | 2020-11-27 | — | — | CN | claimed |
| US-20140294765-A1 | LSR ANTIBODIES, AND USES THEREOF FOR TREATMENT OF CANCER | COMPUGEN LTD. (IL) | 2014-10-02 | — | — | US | claimed |
| WO-2014154804-A1 | PHARMACEUTICAL FORMULATION FOR USE IN THE TREATMENT AND/OR PREVENTION OF RESTENOSIS | CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (C.H.U.V) (CH) | 2014-10-02 | — | — | WO | claimed |
| EP-2756093-A2 | C10RF32 ANTIBODIES, AND USES THEREOF FOR TREATMENT OF CANCER | Compugen Ltd. (IL) | 2014-07-23 | — | — | EP | claimed |
| EP-2744830-A1 | LSR ANTIBODIES, AND USES THEREOF FOR TREATMENT OF CANCER | Compugen Ltd. (IL) | 2014-06-25 | — | — | EP | claimed |
| WO-2013114367-A9 | C10RF32 ANTIBODIES, AND USES THEREOF FOR TREATMENT OF CANCER | COMPUGEN LTD. (IL) | 2014-04-24 | — | — | WO | claimed |
| WO-2013190555-A1 | LSR ANTIBODIES, AND USES THEREOF FOR TREATMENT OF CANCER | COMPUGEN LTD. (IL) | 2013-12-27 | — | — | WO | claimed |
| WO-2013114367-A2 | C10RF32 ANTIBODIES, AND USES THEREOF FOR TREATMENT OF CANCER | COMPUGEN LTD. (IL) | 2013-08-08 | — | — | WO | claimed |
| EP-0825866-A1 | COMBINED PREPARATIONS WITH VASCULAR EFFECT CONTAINING DIHYDROPYRIDINES, ACETYLSALICYLIC ACID NITROESTERS AND VITAMINS | BAYER AG (DE) | 1998-03-04 | — | — | EP | claimed |
| CN-1144092-A | Non-steroid anti-inflammatory agents capable of releasing nitric oxide, their preparing method and use | CAI XIONG (CN) | 1997-03-05 | — | — | CN | claimed |
| WO-1996034607-A1 | COMBINED PREPARATIONS WITH VASCULAR EFFECT CONTAINING DIHYDROPYRIDINES, ACETYLSALICYLIC ACID NITROESTERS AND VITAMINS | BAYER AKTIENGESELLSCHAFT (DE) | 1996-11-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220202838-A1 | COMBINATIONAL THERAPIES FOR TREATMENT OF CANCER COMPRISING A BACTERIOCHLOROPHYLL DERIVATIVE | VHL, MYADM, PPOX | PTGS2 244/4885HSD17B10 2690/4885KDM4E 1600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.